Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20630801 | 0.93 | HSD17B1 (0.59) | ESR1ESR2LMNAHPGDMAPT | |
| SCHEMBL10031827 | 0.89 | PGR (0.47) | LMNAELANECA2MAPK1CES2 | |
| SCHEMBL129749 | 0.83 | ESR1 (0.50) | ESR1ESR2LMNAHPGDMAPT | |
| SCHEMBL8519631 | 0.83 | ESR1 (0.50) | ESR1ESR2LMNAHPGDMAPT | |
| SCHEMBL10483771 | 0.82 | ELANE (0.54) | ESR1ESR2LMNAHPGDMAPT | |
| SCHEMBL15745797 | 0.82 | PGR (0.51) | HPGDMAPTHTTELANECA1 | |
| SCHEMBL5058744 | 0.82 | PGR (0.43) | LMNAELANECA2MAPK1CES2 | |
| SCHEMBL27946891 | 0.81 | ESR1 (0.48) | ESR1ESR2LMNAHPGDMAPT | |
| SCHEMBL1701967 | 0.80 | CA2 (0.57) | LMNAHPGDMAPTPKMHTT | |
| SCHEMBL1665113 | 0.80 | TSHR (0.60) | HPGDCA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025903-A1 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| WO-2006016708-A1 | FUNGICIDAL COMPOSITION CONTAINING ACID AMIDE DERIVATIVE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-02-16 | — | — | WO | disclosed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| CN-1151130-C | Neuroprotective 3- (piperidinyl-1) -chroman-4, 7-diol and 1- (4-hydroxyphenyl) -2- (piperidinyl-1) alkanol derivatives | ������ҩ������˾ | 2004-05-26 | — | — | CN | disclosed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5925691-A | MIXING WITH REFRACTORY AN ALKALINE PHENOL-ALDEHYDE RESIN PRODUCED BY THE COPOLYCONDENSATION OF: A PHENOL, POLYHYDRIC PHENOL, OR ALKYLPHENOL WITH A BISPHENOL AND AN ALDEHYDE COMPOUND; FLOWABILITY AND FILLING PROPERTIES | KAO CORPORATION (JP) | 1999-07-20 | — | — | US | disclosed |
| CN-1155279-A | Neuroprotective 3-(piperidinyl-1)-chroman-4,7,-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkane alcohol | PFIZER (US) | 1997-07-23 | — | — | CN | disclosed |
| US-4211879-A | Esters of prostacyclin-type compounds | THE UPJOHN COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| EP-0009869-A2 | Esters of prostaglandin-type compounds | THE UPJOHN COMPANY (US) | 1980-04-16 | — | — | EP | disclosed |
| US-4180657-A | Acyl-substituted phenyl esters of prostacyclin-type compounds | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | ESR1 3911/4885ESR2 2569/4885LMNA 1670/4885 |
| US-20240025903-A1 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | HDGF, HGF, BDNF | ESR1 1458/4885ESR2 168/4885LMNA 1247/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | ESR1 1065/4885ESR2 1166/4885LMNA 3107/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | ESR1 1274/4885ESR2 1220/4885LMNA 3139/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | ESR1 571/4885ESR2 183/4885LMNA 3747/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | ESR1 1274/4885ESR2 1220/4885LMNA 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.